Home › Urothelial (Transitional Cell) Carcinoma › California › Santa Barbara
Urothelial (Transitional Cell) Carcinoma clinical trials in Santa Barbara, CA
4 studies for Urothelial (Transitional Cell) Carcinoma are looking for participants at sites in and around Santa Barbara (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #59, Santa Barbara
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
RecruitingPhase 3
- Samsun Clinic - Ridley-Tree Cancer Center, Santa Barbara
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
RecruitingPhase 1/2
- UCLA Hematology/Oncology- Santa Barbara, Santa Barbara
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
RecruitingPhase 2
- UCLA Montecito Primary & Specialty Care, Montecito · 4 mi away
Urothelial (Transitional Cell) Carcinoma trials in other cities
- Nashville, TN23 studies
- New York City, NY22 studies
- Houston, TX19 studies
- Dallas, TX18 studies
- Edison, NJ18 studies
- Los Angeles, CA17 studies
- Queens, NY15 studies
- Chicago, IL14 studies
- Arlington, VA12 studies
- Boston, MA11 studies
- San Antonio, TX11 studies
- Austin, TX10 studies
Other studies in Santa Barbara
- Cancer (all types)7 studies
- Breast Cancer6 studies
- Non-Small Cell Lung Cancer5 studies
- Ovarian Cancer5 studies
- Prostate Cancer3 studies
- Type 2 Diabetes3 studies
- Pulmonary Hypertension3 studies
- Pulmonary Arterial Hypertension3 studies
- Endometrial Cancer3 studies
- Bladder Cancer3 studies
- Metastatic Cancer3 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.